{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:33:43Z","timestamp":1793648023455,"version":"4.5.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA174523, U54 CA224070"],"award-info":[{"award-number":["P50 CA174523, U54 CA224070"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA010815"],"award-info":[{"award-number":["CA010815"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PRCRP WX1XWH-16-1-0119 [CA150619], W81XWH-16-1-0120 and W81XWH-16-1-0121"],"award-info":[{"award-number":["PRCRP WX1XWH-16-1-0119 [CA150619], W81XWH-16-1-0120 and W81XWH-16-1-0121"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse melanoma model by injecting fetal liver-derived CD34<jats:sup>+<\/jats:sup> cells and implanting autologous thymus in immune-deficient NOD-<jats:italic>scid<\/jats:italic> IL2R\u03b3<jats:sup>null<\/jats:sup> (NSG) mice. Reconstituted Hu-mice are challenged with HLA-matched melanomas and treated with anti-PD-1, which results in restricted tumor growth but not complete regression. Tumor RNA-seq, multiplexed imaging and immunohistology staining show high expression of chemokines, as well as recruitment of FOXP3<jats:sup>+<\/jats:sup> Treg and mast cells, in selective tumor regions. Reduced HLA-class I expression and CD8<jats:sup>+<\/jats:sup>\/Granz B<jats:sup>+<\/jats:sup> T cells homeostasis are observed in tumor regions where FOXP3<jats:sup>+<\/jats:sup> Treg and mast cells co-localize, with such features associated with resistance to anti-PD-1 treatment. Combining anti-PD-1 with sunitinib or imatinib results in the depletion of mast cells and complete regression of tumors. Our results thus implicate mast cell depletion for improving the efficacy of anti-PD-1 therapy.<\/jats:p>","DOI":"10.1038\/s41467-020-20600-7","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T18:36:08Z","timestamp":1610476568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Rajasekharan","family":"Somasundaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeree","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1553-4366","authenticated-orcid":false,"given":"Anastasia","family":"Samarkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdel-Mohsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilda","family":"Beqiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan","family":"Kiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5671-928X","authenticated-orcid":false,"given":"Michela","family":"Perego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Brafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Secreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenn","family":"Danet-Desnoyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Traum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H.","family":"Kaestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denitsa","family":"Hristova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9949-798X","authenticated-orcid":false,"given":"Joshua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Fukunaga-Kalabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ping-Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito W.","family":"Rebecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthi","family":"Vonteddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-2219","authenticated-orcid":false,"given":"Farokh","family":"Dotiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Dweep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayamanna","family":"Wickramasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew V.","family":"Kossenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Reyes-Arbujas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenisha","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-9511","authenticated-orcid":false,"given":"Johannes","family":"Griss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Keeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-8512","authenticated-orcid":false,"given":"David","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5799-6759","authenticated-orcid":false,"given":"Luis J.","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9964-580X","authenticated-orcid":false,"given":"Qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3729-2249","authenticated-orcid":false,"given":"Lukas","family":"Peiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-0912","authenticated-orcid":false,"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-2065","authenticated-orcid":false,"given":"Kar","family":"Muthumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-7576","authenticated-orcid":false,"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-6407","authenticated-orcid":false,"given":"Dmitry","family":"Gabrilovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenhard","family":"Herlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"20600_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"20600_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00452-4","volume":"8","author":"R Somasundaram","year":"2017","unstructured":"Somasundaram, R. et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat. Commun. 8, 607 (2017).","journal-title":"Nat. Commun."},{"key":"20600_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel, J. A., Otsuka, A. & Kabashima, K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front. Oncol. 8, 86 (2018).","journal-title":"Front. Oncol."},{"key":"20600_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9\u201316 (2018).","journal-title":"Br. J. Cancer"},{"key":"20600_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.trecan.2020.02.001","volume":"6","author":"LA Horn","year":"2020","unstructured":"Horn, L. A., Fousek, K. & Palena, C. Tumor plasticity and resistance to immunotherapy. Trends Cancer 6, 432\u2013441 (2020).","journal-title":"Trends Cancer"},{"key":"20600_CR6","doi-asserted-by":"crossref","unstructured":"Fares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P. & Hu-Lieskovan, S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am. Soc. Clin. Oncol. Educ. Book 39, 147\u2013164 (2019).","DOI":"10.1200\/EDBK_240837"},{"key":"20600_CR7","doi-asserted-by":"publisher","first-page":"e1299303","DOI":"10.1080\/2162402X.2017.1299303","volume":"6","author":"N Jacquelot","year":"2017","unstructured":"Jacquelot, N. et al. Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. Oncoimmunology 6, e1299303 (2017).","journal-title":"Oncoimmunology"},{"key":"20600_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00608-2","volume":"8","author":"N Jacquelot","year":"2017","unstructured":"Jacquelot, N. et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat. Commun. 8, 592 (2017).","journal-title":"Nat. Commun."},{"key":"20600_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"20600_CR10","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.4049\/jimmunol.1302847","volume":"192","author":"J Mu","year":"2014","unstructured":"Mu, J. et al. Regulation of MHC class I expression by Foxp3 and its effect on regulatory T cell function. J. Immunol. 192, 2892\u20132903 (2014).","journal-title":"J. Immunol."},{"key":"20600_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382\u2013386 (2018).","journal-title":"Nature"},{"key":"20600_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med 25, 454\u2013461 (2019).","journal-title":"Nat. Med"},{"key":"20600_CR13","doi-asserted-by":"crossref","unstructured":"Martini, D. J. et al. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Invest. New Drugs 37, 1198\u20131206 (2019).","DOI":"10.1007\/s10637-019-00736-0"},{"key":"20600_CR14","doi-asserted-by":"crossref","unstructured":"Weiss, S. A., Wolchok, J. D. & Sznol, M. Immunotherapy of melanoma: facts and hopes. Clin. Cancer Res. 25, 5191\u20135201 (2019).","DOI":"10.1158\/1078-0432.CCR-18-1550"},{"key":"20600_CR15","doi-asserted-by":"publisher","first-page":"025017","DOI":"10.1088\/1361-6560\/aaf96c","volume":"64","author":"D Valentinuzzi","year":"2019","unstructured":"Valentinuzzi, D. et al. Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. Phys. Med Biol. 64, 025017 (2019).","journal-title":"Phys. Med Biol."},{"key":"20600_CR16","first-page":"81","volume":"8","author":"OF Kuzu","year":"2015","unstructured":"Kuzu, O. F., Nguyen, F. D., Noory, M. A. & Sharma, A. Current state of animal (mouse) modeling in melanoma research. Cancer Growth Metastasis 8, 81\u201394 (2015).","journal-title":"Cancer Growth Metastasis"},{"key":"20600_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev-pathol-052016-100332","volume":"12","author":"NC Walsh","year":"2017","unstructured":"Walsh, N. C. et al. Humanized mouse models of clinical disease. Annu Rev. Pathol. 12, 187\u2013215 (2017).","journal-title":"Annu Rev. Pathol."},{"key":"20600_CR18","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1096\/fj.201700740R","volume":"32","author":"M Wang","year":"2018","unstructured":"Wang, M. et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 32, 1537\u20131549 (2018).","journal-title":"FASEB J."},{"key":"20600_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nbt.2858","volume":"32","author":"A Rongvaux","year":"2014","unstructured":"Rongvaux, A. et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32, 364\u2013372 (2014).","journal-title":"Nat. Biotechnol."},{"issue":"Suppl 2","key":"20600_CR20","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1093\/infdis\/jit319","volume":"208","author":"MA Brehm","year":"2013","unstructured":"Brehm, M. A., Shultz, L. D., Luban, J. & Greiner, D. L. Overcoming current limitations in humanized mouse research. J. Infect. Dis. 208(Suppl 2), S125\u2013S130 (2013).","journal-title":"J. Infect. Dis."},{"key":"20600_CR21","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1128\/IAI.01322-15","volume":"84","author":"M Xia","year":"2016","unstructured":"Xia, M. et al. A subset of protective gamma9delta2 T cells is activated by novel mycobacterial glycolipid components. Infect. Immun. 84, 2449\u20132462 (2016).","journal-title":"Infect. Immun."},{"key":"20600_CR22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3389\/fimmu.2018.01305","volume":"9","author":"CD Pauza","year":"2018","unstructured":"Pauza, C. D. et al. Gamma delta T cell therapy for cancer: it is good to be local. Front. Immunol. 9, 1305 (2018).","journal-title":"Front. Immunol."},{"key":"20600_CR23","doi-asserted-by":"publisher","first-page":"e1083670","DOI":"10.1080\/2162402X.2015.1083670","volume":"5","author":"J Thalmensi","year":"2016","unstructured":"Thalmensi, J. et al. Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Oncoimmunology 5, e1083670 (2016).","journal-title":"Oncoimmunology"},{"key":"20600_CR24","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph, R. W. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. 24, 4960\u20134967 (2018).","journal-title":"Clin. Cancer Res."},{"key":"20600_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 1711, 243\u2013259 (2018).","journal-title":"Methods Mol. Biol."},{"key":"20600_CR26","first-page":"424","volume":"8","author":"G Varricchi","year":"2017","unstructured":"Varricchi, G. et al. Are mast cells MASTers in cancer? Front. Immunol. 8, 424 (2017).","journal-title":"Front. Immunol."},{"key":"20600_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/exd.13107","volume":"26","author":"G Varricchi","year":"2017","unstructured":"Varricchi, G. et al. Controversial role of mast cells in skin cancers. Exp. Dermatol 26, 11\u201317 (2017).","journal-title":"Exp. Dermatol"},{"key":"20600_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/bjc.2015.193","volume":"113","author":"SC Wightman","year":"2015","unstructured":"Wightman, S. C. et al. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br. J. Cancer 113, 327\u2013335 (2015).","journal-title":"Br. J. Cancer"},{"key":"20600_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.semcancer.2008.11.002","volume":"19","author":"R Somasundaram","year":"2009","unstructured":"Somasundaram, R. & Herlyn, D. Chemokines and the microenvironment in neuroectodermal tumor-host interaction. Semin. Cancer Biol. 19, 92\u201396 (2009).","journal-title":"Semin. Cancer Biol."},{"key":"20600_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fmed.2018.00271","volume":"5","author":"PT Kuo","year":"2018","unstructured":"Kuo, P. T. et al. The role of CXCR3 and its chemokine ligands in skin disease and cancer. Front. Med. 5, 271 (2018).","journal-title":"Front. Med."},{"key":"20600_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949.e916 (2017).","journal-title":"Cell"},{"key":"20600_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"20600_CR33","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko, J. S. et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148\u20132157 (2009).","journal-title":"Clin. Cancer Res."},{"key":"20600_CR34","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","volume":"14","author":"JH Finke","year":"2008","unstructured":"Finke, J. H. et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14, 6674\u20136682 (2008).","journal-title":"Clin. Cancer Res."},{"key":"20600_CR35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4049\/immunohorizons.2000026","volume":"4","author":"DA Armstrong","year":"2020","unstructured":"Armstrong, D. A. et al. Extracellular vesicles from Pseudomonas aeruginosa suppress MHC-related molecules in human lung macrophages. Immunohorizons 4, 508\u2013519 (2020).","journal-title":"Immunohorizons"},{"key":"20600_CR36","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1158\/1078-0432.CCR-14-1554","volume":"21","author":"T Wang","year":"2015","unstructured":"Wang, T. et al. BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth. Clin. Cancer Res. 21, 1652\u20131664 (2015).","journal-title":"Clin. Cancer Res."},{"key":"20600_CR37","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1021\/mp200421k","volume":"8","author":"EH Flach","year":"2011","unstructured":"Flach, E. H., Rebecca, V. W., Herlyn, M., Smalley, K. S. & Anderson, A. R. Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol. Pharm. 8, 2039\u20132049 (2011).","journal-title":"Mol. Pharm."},{"key":"20600_CR38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-18-0619","volume":"7","author":"SM Reddy","year":"2019","unstructured":"Reddy, S. M. et al. Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. Cancer Immunol. Res. 7, 1025\u20131035 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"20600_CR39","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2353\/ajpath.2010.100070","volume":"177","author":"A Johansson","year":"2010","unstructured":"Johansson, A. et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am. J. Pathol. 177, 1031\u20131041 (2010).","journal-title":"Am. J. Pathol."},{"key":"20600_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.cmet.2019.01.003","volume":"29","author":"YJ Wang","year":"2019","unstructured":"Wang, Y. J. et al. Multiplexed in situ imaging mass cytometry analysis of the human endocrine pancreas and immune system in type 1 diabetes. Cell Metab. 29, 769\u2013783 e764 (2019).","journal-title":"Cell Metab."},{"key":"20600_CR41","doi-asserted-by":"publisher","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","volume":"65","author":"D Fang","year":"2005","unstructured":"Fang, D. et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328\u20139337 (2005).","journal-title":"Cancer Res."},{"key":"20600_CR42","first-page":"e991","volume":"3","author":"Q Chen","year":"2013","unstructured":"Chen, Q. & Chen, J. Isolation of CD34+ cells from human fetal liver and cord blood. Bio-Protoc. 3, e991 (2013).","journal-title":"Bio-Protoc."},{"key":"20600_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/mt.2013.218","volume":"22","author":"TL Wu","year":"2014","unstructured":"Wu, T. L. et al. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors\u2019 genome. Mol. Ther. 22, 42\u201351 (2014).","journal-title":"Mol. Ther."},{"key":"20600_CR44","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1073\/pnas.90.7.2842","volume":"90","author":"MJ Browning","year":"1993","unstructured":"Browning, M. J. et al. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc. Natl Acad. Sci. USA 90, 2842\u20132845 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"20600_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"20600_CR46","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1093\/bioinformatics\/btv309","volume":"31","author":"L Kuchenbecker","year":"2015","unstructured":"Kuchenbecker, L. et al. IMSEQ\u2014a fast and error aware approach to immunogenetic sequence analysis. Bioinformatics 31, 2963\u20132971 (2015).","journal-title":"Bioinformatics"},{"key":"20600_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nature22976","volume":"547","author":"J Glanville","year":"2017","unstructured":"Glanville, J. et al. Identifying specificity groups in the T cell receptor repertoire. Nature 547, 94\u201398 (2017).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20600-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:07:59Z","timestamp":1669975679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20600-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["20600"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-20600-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.D. has been a consultant to Roche\/Genentech, Array, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, and Apexigen, and he has been the PI of research grants to MD Anderson by Roche\/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, and Oncothyreon. M.T.T. has advisory board relationships with Nanostring, Merck, Bristol Meyers, and Myriad Genetics. J.A.W. serves as a consultant\/advisory board member for Roche\/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals and Microbiome DX., and has research support from GlaxoSmithKline, Roche\/Genentech, Bristol-Myers Squibb, and Novartis. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}